These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19333002)

  • 41. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America.
    Macías M; Lanata CF; Zambrano B; Gil AI; Amemiya I; Mispireta M; Ecker L; Santos-Lima E
    Pediatr Infect Dis J; 2012 Aug; 31(8):e126-32. PubMed ID: 22531237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
    Klein NP; Abu-Elyazeed R; Cornish M; Leonardi ML; Weiner LB; Silas PE; Grogg SE; Varman M; Frenck RW; Cheuvart B; Baine Y; Miller JM; Leyssen M; Mesaros N; Roy-Ghanta S
    Vaccine; 2017 Jun; 35(28):3564-3574. PubMed ID: 28536030
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: results from four phase III multicenter trials across three continents.
    Ortega-Barrìa E; Kanra G; Leroux G; Bravo L; Safary A; Lefevre I;
    Vaccine; 2007 Dec; 25(50):8432-40. PubMed ID: 17961876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and reactogenicity of a combined fully liquid DTPw-HepB-Hib pentavalent vaccine in healthy infants: no clinically relevant impact of a birth dose of hepatitis B vaccine.
    Gentile A; Umido V; Czerniuk P; Nacul J; Seigelchifer M; Hilbert AK; Yela U; Herzog C; Aeberhard U; Spyr C
    Int J Infect Dis; 2011 Jan; 15(1):e24-9. PubMed ID: 21093342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparative clinical study to assess safety and reactogenicity of a DTwP-HepB+Hib vaccine.
    Dalvi S; Kulkarni PS; Phadke MA; More SS; Lalwani SK; Jain D; Manglani M; Garg BS; Doibale MK; Deshmukh CT;
    Hum Vaccin Immunother; 2015; 11(4):901-7. PubMed ID: 25933183
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety monitoring of a new pentavalent vaccine in the expanded programme on immunisation in Ghana.
    Dodoo AN; Renner L; van Grootheest AC; Labadie J; Antwi-Agyei KO; Hayibor S; Addison J; Pappoe V; Appiah-Danquah A
    Drug Saf; 2007; 30(4):347-56. PubMed ID: 17408311
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DTwP-HB-Hib: antibody persistence after a primary series, immune response and safety after a booster dose in children 18-24 months old.
    Gunardi H; Rusmil K; Fadlyana E; Soedjatmiko ; Dhamayanti M; Sekartini R; Tarigan R; Satari HI; Medise BE; Sari RM; Bachtiar NS; Kartasasmita CB; Hadinegoro SRS
    BMC Pediatr; 2018 May; 18(1):177. PubMed ID: 29804542
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial.
    Langley JM; Halperin SA; Rubin E; White C; McNeil S; Mutch J; Mackinnon-Cameron D; Smith B
    Pediatr Infect Dis J; 2012 Feb; 31(2):189-92. PubMed ID: 22173143
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lot-to-lot consistency study of the fully liquid pentavalent DTwP-HepB-Hib vaccine Quinvaxem (®) demonstrating clinical equivalence, suitability of the vaccine as a booster and concomitant administration with measles vaccine.
    Aspinall S; Traynor D; Bedford P; Hartmann K
    Hum Vaccin Immunother; 2012 Aug; 8(8):1109-18. PubMed ID: 22854660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety.
    Mallet E; Belohradsky BH; Lagos R; Gothefors L; Camier P; Carrière JP; Kanra G; Hoffenbach A; Langue J; Undreiner F; Roussel F; Reinert P; Flodmark CE; Stojanov S; Liese J; Levine MM; Muñoz A; Schödel F; Hessel L;
    Vaccine; 2004 Mar; 22(11-12):1343-57. PubMed ID: 15063556
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China.
    Li RC; Li FX; Li YP; Hou QM; Li CG; Li YN; Chen FS; Hu XZ; Su WB; Zhang SM; Fang HH; Ye Q; Zeng TD; Liu TX; Li XB; Huang YN; Deng ML; Zhang YP; Ortiz E
    Vaccine; 2011 Feb; 29(10):1913-20. PubMed ID: 21219984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults.
    Aguilar-Betancourt A; González-Delgado CA; Cinza-Estévez Z; Martínez-Cabrera J; Véliz-Ríos G; Alemán-Zaldívar R; Alonso-Martínez MI; Lago-Baños M; Puble-Alvarez N; Delahanty-Fernandez A; Juvier-Madrazo AI; Ortega-León D; Olivera-Ruano L; Correa-Fernández A; Abreu-Reyes D; Soto-Mestre E; Pérez-Pérez MV; Figueroa-Baile N; Pérez LH; Rodríguez-Silva A; Martínez-Díaz E; Guillén-Nieto GE; Muzio-González VL
    Hum Vaccin; 2008; 4(1):54-9. PubMed ID: 18441530
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the immunogenicity and safety of pentavalent vaccine Quinvaxem in a compact prefilled auto-disabled (cPAD) injection system versus single-dose vials in healthy infants: a phase 3, open-label, randomized, parallel-group, non-inferiority study.
    Capeding MR; Alberto E; Versteilen A; Rauscher M; Bagchi P; Palacios PI
    Int J Infect Dis; 2016 May; 46():71-8. PubMed ID: 26923083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children.
    Gatchalian SR; Ramakrishnan G; Bock HL; Lefevre I; Jacquet JM
    Hum Vaccin; 2010 Aug; 6(8):664-72. PubMed ID: 20657177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and immunogenicity of a new fully liquid DTPw-HepB-Hib combination vaccine in infants.
    Kanra G; Kara A; Demiralp O; Contorni M; Hilbert AK; Spyr C; Viviani S
    Hum Vaccin; 2006; 2(4):155-60. PubMed ID: 17012890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6-8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority study.
    Susarla SK; Gupta M; Mantan M; Dhongade R; Bhave S; Das RK; Ray RK; Ramesh Babu T; Ravi MD; Krishnamurthy B; James S; Sandhya G; Satish M; Sahoo DP
    Vaccine; 2019 Aug; 37(36):5452-5459. PubMed ID: 31331773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of safety and immunogenicity of two different lots of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine manufactured using small and large scale manufacturing process.
    Sharma HJ; Patil VD; Lalwani SK; Manglani MV; Ravichandran L; Kapre SV; Jadhav SS; Parekh SS; Ashtagi G; Malshe N; Palkar S; Wade M; Arunprasath TK; Kumar D; Shewale SD
    Vaccine; 2012 Jan; 30(3):510-6. PubMed ID: 22119927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.